Downloads: 92

Files in This Item:
File Description SizeFormat 
s12886-018-0914-z.pdf851.66 kBAdobe PDFView/Open
Title: Long-term efficacy and safety of anti-VEGF therapy in retinitis pigmentosa: a case report
Authors: Miyata, Manabu  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-7574-1749 (unconfirmed)
Oishi, Akio
Oishi, Maho
Hasegawa, Tomoko
Ohashi Ikeda, Hanako
Tsujikawa, Akitaka  kyouindb  KAKEN_id
Author's alias: 宮田, 学
大石, 明生
大石, 真秀
長谷川, 智子
池田, 華子
辻川, 明孝
Keywords: Retinitis pigmentosa
Anti-VEGF therapy
Choroidal neovascularization
Long-term
PRPH2
Issue Date: 14-Sep-2018
Publisher: BMC
Journal title: BMC ophthalmology
Volume: 18
Thesis number: 248
Abstract: [Background]Retinitis pigmentosa (RP), a neurodegenerative disease, is occasionally accompanied by choroidal neovascularization (CNV) and cystoid macular oedema. It is presently treated with repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents. However, there are concerns regarding long-term inhibition of VEGF by the use of these agents, especially in cases involving neurodegenerative diseases, since VEGFs have a neuroprotective effect. Currently, there are no reports on the long-term safety of anti-VEGF therapy in patients with RP. [Case presentation]In this report, we describe the case of a 56-year-old female patient with CNV associated with RP who was treated with anti-VEGF therapy for 8 years. She had autosomal dominant RP with a heterozygous PRPH2 mutation (c.410G > A) and complained of metamorphopsia in her left eye. Examinations revealed CNV with serous retinal detachment. She was treated with as-needed injections for 2 years; however, she experienced a recurrence. Therefore, we switched to a bimonthly regimen that was continued for 6 years. In total, the patient received 34 injections of various types of anti-VEGFs over 8 years. No recurrences were noted during that time, and we have not detected any negative effects concerning the progression of visual field loss in comparison with the fellow eye. [Conclusions]No negative effects related to the progression of visual field loss were observed during continuous treatment with anti-VEGF agents for 8 years in our patient.
Rights: © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
URI: http://hdl.handle.net/2433/234583
DOI(Published Version): 10.1186/s12886-018-0914-z
PubMed ID: 30217183
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.